Jeremy Whitty
Acting Programme Director, MSc in Global Medicines Development
Jeremy Whitty is the Acting Programme Director of the online MSc in Global Medicines Development and he is responsible for the design, development, and delivery of the programme. His work focuses on equipping students with the scientific and leadership skills needed to navigate the complexities of global medicines development.
He is also supporting the development of the Global Medicines Development Network, an initiative founded by the Centre for Pharmaceutical Medicine Research at King’s. The network will transform global drug development by building equitable and sustainable educational and research capacity worldwide, connecting universities, industry, and policy-makers and help improve access to innovative medicines for all.
Jeremy has 30 years’ experience working in academia and the pharmaceutical industry and he has held academic positions at institutions such as Karolinska Institutet, the University of the Western Cape, Oxford University and IE Business School in Madrid.
With industry experience in vaccines, biologics and medical devices his expertise spans pharmaceutical science and technology, clinical operations, regulatory science and more recently, the commercialisation of Advanced Therapy Medicinal Products (ATMPs).
Research interests
Jeremy’s research addresses critical challenges in the commercialisation of Advanced Therapy Medicinal Products (ATMPs), exploring innovative strategies to improve decision-making processes. Inspired by public-private partnership models developed during COVID-19 vaccine initiatives, his research emphasises early engagement with Health Technology Assessment (HTA) bodies and healthcare payers.
Hybrid Decision-Making Frameworks for ATMP Commercialisation
Centres on decision-support frameworks to address the complexities inherent in the commercialisation of ATMPs.
His approach integrates Real Options Analysis to provide strategic flexibility. This allows decision-makers to dynamically adjust investment decisions as new clinical evidence, regulatory feedback, or market conditions emerge.
Drawing insights from successful COVID-19 vaccine-development partnerships, his research shows the advantages of early engagement and evidence co-creation with Health Technology Assessment (HTA) bodies—such as NICE in the UK or HIQA in Ireland to help reduce market-entry uncertainties.
Quantitative Analytical Techniques: Real Options and Stochastic Simulations
Involves the application of real options theory complemented by stochastic simulation methods, game theory, multi-criteria-decision-analysis and predictive analytics.
These tools provide robust insights into investment decisions under conditions of scientific and market uncertainty and regulatory complexity—typical challenges in ATMP development.
Career highlights
- Jeremy currently leads the design, development, and delivery of the MSc in Global Medicines Development at King’s College London.
- He led the Regulatory Science Programme at the University of the Western Cape and the ClinOps Programme with CDT-Africa at Addis Adiba University.
- He recently developed a sustainable business model for bio-manufacturing training centres in Africa in collaboration with GIZ, the German Development Agency.
- He has supported over 100 clinical trials, mostly in resource constrained settings.
- He has also supervised over 150 MSc research theses.
- He has designed and delivered advanced programmes in drug discovery, drug dosage, pharmacometrics and clinical trial management
- He was Professor of Operations and Quality in the Health Sciences at IE Business School, Madrid.
- In industry he held many senior roles in engineering and research and development.